Sterling Biotech reports standalone net profit of Rs 36.97 crore in the December 2018 quarter
11 - Feb - 2019 12:00 | 2285 days ago
Net profit of Sterling Biotech reported to Rs 36.97 crore in the quarter ended December 2018 as against net loss of Rs 168.02 crore during the previous quarter ended December 2017. Sales rose 8.38% to Rs 94.95 crore in the quarter ended December 2018 as against Rs 87.61 crore during the previous quarter ended December 2017.
Sterling Biotech announced the initiation of Corporate Insolvency Resolution Process by NCLT with effect from 11 June 2018. Sundaresh Bhat has been appointed as the Interim Resolution Professional and as such the powers of the board are suspended and shall be exercised by the IRP.
Sterling Biotech announced the initiation of Corporate Insolvency Resolution Process by NCLT with effect from 11 June 2018. Sundaresh Bhat has been appointed as the Interim Resolution Professional and as such the powers of the board are suspended and shall be exercised by the IRP.
Sterling Biotech reports standalone net profit of Rs 36.97 crore in the December 2018 quarter
11 - Feb - 2019 12:00 | 2285 days ago
Net profit of Sterling Biotech reported to Rs 36.97 crore in the quarter ended December 2018 as against net loss of Rs 168.02 crore during the previous quarter ended December 2017. Sales rose 8.38% to Rs 94.95 crore in the quarter ended December 2018 as against Rs 87.61 crore during the previous quarter ended December 2017.
Sterling Biotech announced the initiation of Corporate Insolvency Resolution Process by NCLT with effect from 11 June 2018. Sundaresh Bhat has been appointed as the Interim Resolution Professional and as such the powers of the board are suspended and shall be exercised by the IRP.
Sterling Biotech reports standalone net profit of Rs 36.97 crore in the December 2018 quarter
11 - Feb - 2019 12:00 | 2285 days ago
Net profit of Sterling Biotech reported to Rs 36.97 crore in the quarter ended December 2018 as against net loss of Rs 168.02 crore during the previous quarter ended December 2017. Sales rose 8.38% to Rs 94.95 crore in the quarter ended December 2018 as against Rs 87.61 crore during the previous quarter ended December 2017.
Sterling Biotech announced the initiation of Corporate Insolvency Resolution Process by NCLT with effect from 11 June 2018. Sundaresh Bhat has been appointed as the Interim Resolution Professional and as such the powers of the board are suspended and shall be exercised by the IRP.
Sterling Biotech announced the initiation of Corporate Insolvency Resolution Process by NCLT with effect from 11 June 2018. Sundaresh Bhat has been appointed as the Interim Resolution Professional and as such the powers of the board are suspended and shall be exercised by the IRP.
